Abstract:
본 발명은 탄닌(tannin), 또는 탄닌 유래 갈산(gallic acid) 또는 엘라그산(ellagic acid)을 포함하는 동맥경화증, 고지혈증 및 간 질환의 예방 및 치료용 조성물에 관한 것으로, 탄닌, 갈산 또는 엘라그산은 동물에게 투여되었을 때 동맥내피에 대식세포-지질 복합체가 침착되는 것을 강력히 억제할 뿐만 아니라, 동물의 혈청 GOT(glutamate-oxaloacetate transaminase), GPT(glutamate-pyruvate transaminase), γGTP(γ-glutamyl transpeptidase) 및 혈중 지질의 농도를 낮추고, 간세포의 손상 및 지방간화를 강력히 억제하므로, 본 발명의 조성물은 동맥경화증, 고지혈증 및 간 질환의 예방 및 치료제로서 유용하게 사용될 수 있다.
Abstract:
PURPOSE: A food or drink composition including a bioflavonoid of formula(I) or extract of vegetables or citrus fruits containing the bioflavonoid is provided. This composition prevents hypertension, arteriosclerosis and a stroke of paralysis by increasing the plasma high density lipoprotein level in the body. CONSTITUTION: The composition for increasing plasma high density lipoprotein(HDL) level comprises a bioflavonoid of formula(I), wherein i) R1 to R9 are each independently hydrogen; hydroxy group; C1-9 alkoxy group optionally substituted with one or more substituents selected from the group consisting of hydroxy, C1-5 alkoxy, aryloxy, and phenyl group substituted with 1 to 3 substituents selected from the group consisting of a hydroxy, alkoxy, aryloxy, halogen, nitro and amido group; a C5-9 cycloalkyloxy group substituted with 1 to 3 substituents selected from the group consisting of a hydroxy, alkoxy, aryloxy, halogen, nitro and amido group; C5-9 cycloalkylcarbonyloxy group substituted with 1 to 3 substituents selected from the group consisting of a hydroxy, alkoxy, aryloxy, halogen, nitro and amido group; C2-10 or C16-18 acyloxy group optionally substituted with one or more substituents selected from the group consisting of a hydroxy, C1-5 alkoxy, aryloxy, and phenyl group substituted with 1 to 3 substituents selected from the group consisting of a hydroxy, alkoxy, aryloxy, halogen and nitro group; rutinosyl group; or rhaminosyl group, and ii) X is a single or double bond. The bioflavonoid of formula(I) or extract of vegetables or citrus fruits containing the bioflavonoid can be added to various foods or drinks.
Abstract:
PURPOSE: A composition containing orange peel extract for inhibition of acyl CoA:cholesterol-O-acyltransferase(ACAT) is provided, which is useful for preventing and treating various cardiovascular diseases by decreasing blood low density lipoprotein(LDL) cholesterol. CONSTITUTION: A process fro the preparation of composition containing orange peel extract for inhibition of acyl CoA:cholesterol-O-acyltransferase(ACAT) comprises the steps of: washing the peel of tangerine originated in Korea, and drying at normal temperature to get Aurantii Nobilis Pericarpium; adding 95% ethanol, keeping at normal temperature for 24hours, and filtering to get extract and solid residue; extracting the solid residue twice more by the same process, and gathering extracts altogether; and concentrating the extract using a rotary vacuum evaporator under decompression to get concentrated extract containing bio-flavonoids.
Abstract translation:目的:提供含有抑制酰基CoA:胆固醇-O-酰基转移酶(ACAT)的橙皮提取物的组合物,其可用于通过降低血液低密度脂蛋白(LDL)胆固醇来预防和治疗各种心血管疾病。 构成:含有橙皮提取物抑制酰基CoA:胆固醇-O-酰基转移酶(ACAT)的组合物的制备方法包括以下步骤:洗涤起始于韩国的橘皮,并在常温下干燥以得到Aurantii Nobilis Pericarpium; 加入95%乙醇,在常温保持24小时,过滤得到提取物和固体残渣; 通过相同的方法提取固体残渣两次,并收集提取物; 并在减压下使用旋转式真空蒸发器浓缩提取物,得到含有生物黄酮的浓缩提取物。
Abstract:
PURPOSE: A pharmaceutical composition and a functional food comprising diosmin are provided, for treating and preventing hyper lipidemia and arteriosclerosis. CONSTITUTION: The pharmaceutical composition comprises diosmin in effective amount; and pharmaceutically acceptable carriers. The functional food comprises 0.01-10 wt%, preferably 0.1-5 wt% of diosmin. Diosmin inhibits HMG CoA (3-hydroxy-3-methylglutaryl coenzyme) being a reduction enzyme which relates to the biosynthesis of cholesterol and ACAT (acyl CoA; cholesterol-O-acyltransferase) which transforms cholesterol into cholesteryl ester, and reduces the concentration of cholesterol in blood and neutral lipids. Also diosmin strongly inhibits the macrophage-lipid complex from being deposited or adsorbed onto the intra trial surface.
Abstract:
PURPOSE: A pharmaceutical composition and a functional food comprising bioflavonoids are provided, for treating and preventing hyper lipidemia, arteriosclerosis and a liver disease. CONSTITUTION: The pharmaceutical composition comprises rutin, quercetin or their mixture ineffective amount; and pharmaceutically acceptable carriers. The functional food comprises 0.01-10 wt% of rutin, quercetin or their mixture. Rutin can be obtained from a fruit, a leaf, a trunk and a flower of buck wheat and be used in the form of a powder or an extract. Rutin and quercetin being bioflavonoids inhibit HMG CoA (3-hydroxy-3-methylglutaryl coenzyme) being a reduction enzyme which relates to the biosynthesis of cholesterol and ACAT (acyl CoA; cholesterol-O-acyltransferase) which transforms cholesterol into cholesteryl ester in the body. Therefore rutin and quercetin reduce the concentration of cholesterol in blood, inhibit strongly a macrophage-lipid complex from being deposited or adsorbed onto the intra trial surface, and protect a liver.
Abstract:
PURPOSE: A composition is provided to help to improve the blood flow by preventing a platelet cohesion and a formation of a thrombus at the same time. CONSTITUTION: The naringin or the naringenin is effective to prevent and treat the sclerosis of the arteries by the platelet cohesion, and to improve the blood flow by preventing the platelet cohesion generated by collagen. The medical composition is a preventing agent of the platelet cohesion and comprises by mixing the naringin or the naringenin as an efficient component and a carrier permitted for a pharmacology. And a diluent, a disintegrator, a sweetening agent, a lubricant, and a cordial are included.